Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor [6], has been used in first-line treatment of EGFR-mutant non-small cell lung cancer and can significantly improve progression-free survival in patients [57]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.